Disseminated on behalf of Helus Pharma

The System is Broken. Smart Investors Know What to Do Next.

While the establishment fails, new opportunities are created for those who see them.

Dear Reader,

My rich dad taught me one simple lesson: the system is rigged.

It's not rigged against you, specifically. It's just slow, bureaucratic, and designed to protect itself. It rewards insiders and punishes true innovators.

Nowhere is this more obvious than in healthcare.

For decades, the giant pharmaceutical companies, propped up by government regulations and addicted to cheap money from the Fed, got lazy. They stopped taking real risks. They stopped innovating in the areas of greatest need.

Why spend billions trying to solve a complex problem like depression when you can create another "me-too" pill and use your massive marketing budget to push it on doctors?

It's a classic failure of big, bloated institutions. They become financial engineers, not scientists.

But for smart investors, this failure creates a massive opportunity.

Because while the giants slept, a few agile, determined outsiders kept working. They weren't playing the Wall Street game. They were focused on solving a real problem for the millions of people the system left behind.

One of those companies is now on my radar: Helus Pharma (NASDAQ: HELP).

This is not a stock tip. This is financial education. I'm showing you how to spot an asset in a world of paper promises.

See the asset Big Pharma ignored. Get the full story here.

Helus Pharma did what Big Pharma wouldn't. They tackled the hardest problem in mental health: treatment-resistant depression.

And they have achieved a stunning breakthrough.

Their lead drug candidate, HLP003, was granted Breakthrough Therapy Designation by the FDA. The government only gives this "golden ticket" to drugs that show a massive improvement over existing options. It's a signal that even the slow-moving bureaucracy has been forced to recognize the power of this innovation.

The results that earned them this designation are almost hard to believe.

In a clinical study, 71% of patients with severe depression went into complete remission a full year after just two doses. With no significant side effects.

Read that again. This isn't a pill you take every day for the rest of your life. It's a treatment that could provide a lasting solution.

This is more than just a new drug. It's a powerful asset.

In a world where the Fed is printing trillions of fake dollars, the most valuable assets are those that are scarce, protected, and solve a real-world problem. Helus has created one.

They own the intellectual property, over 350 patent filings, that protects this breakthrough until at least 2041. That's a fortress. It's a real asset, not a paper one.

Now, the lazy giants are waking up. They're facing a $300 billion patent cliff and are desperate to buy growth. They're paying billions for innovation they failed to create themselves.

Just look at the recent deals. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies to get its hands on a psychiatric drug. AbbVie paid up to $1.2 billion for a psychedelic-based therapy company. Even Universal Health just dropped $835 million on the virtual mental health platform Talkspace.

The message is clear. Big Pharma needs what Helus has built.

Helus Pharma has what they need. It has a real asset, validated by the FDA, with a major Phase 3 data catalyst coming in the fourth quarter of this year.

The system failed. An opportunity was created. And the smart money is beginning to take notice. Major institutional investors like Point72 and OrbiMed are already backing Helus, and the company has a strong cash position of $195 million to fund its path forward.

Now, you have the information to see it.

Learn more about the asset Big Pharma ignored

To your financial freedom,

Kiyosaki Uncensored

P.S. The rich don't work for money. They acquire assets. In today's economy, a patent-protected drug that solves a crisis for millions is one of the most powerful assets you can find. Helus Pharma (NASDAQ: HELP) built one while the system slept. See the evidence for yourself.

IMPORTANT DISCLAIMER & DISCLOSURES

_{Investing in early-stage technology stocks is HIGH RISK, and past performance does not guarantee future results. Please conduct independent research before making any investment decisions. You could lose all of your investment.}

_{Freedom Financial Research LLC., as a publisher, is not a broker, investment advisor, or financial advisor in any jurisdiction.}

_{Please do not rely on the information presented by Freedom Financial Research as personal investment advice.}

_{If you need personal investment advice, kindly reach out to a qualified and registered broker, investment advisor, or financial advisor.}

_{The communications from Freedom Financial Research should not form the basis of your investment decisions. Examples we provide regarding share price increases related to specific companies are based on randomly selected time periods and should not be taken as an indicator or predictor of future stock prices for those companies.}

_{Helus Pharma is a paid sponsor of this report.}

_{The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom.}

_{Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter. Freedom Financial Research nor any employee of Freedom Financial Research is not registered with the United States Securities and Exchange Commission (the "SEC"): as a "broker-dealer" under the Exchange Act, as an "investment adviser" under the Investment Advisers Act of 1940, or in any other capacity.}

_{Freedom Financial Research, its owners, directors, and employees are also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.}

_{HIGHLY BIASED:}_{In our role, we aim to highlight specific companies for your further investigation; however, these are not stock recommendations, nor do they constitute an offer or sale of the referenced securities. Freedom Financial Research has received cash compensation in the amount of USD $125,000 by a third party, CDMG Inc. for a one-month Helus Pharma profile beginning March 19, 2026 and is thus extremely biased. It is crucial that you conduct your own research prior to investing. This includes reading the companies' SEC filings, press releases, and risk disclosures. The information contained herein regarding Helus Pharma has been derived from its and SEC filings, including scientific and technical information. Information regarding the projects underlying Helus Pharma's interests has been derived from the publicly available disclosure of the underlying operators and owners, including where referenced herein.}

_{Freedom Financial Research, and its directors, employees, and members of their households do not own any shares of Helus Pharma (NASDAQ: HELP).}

_{However, Freedom Financial Research is extremely biased since this is a sponsored editorial.}

_{HIGH RISK:}_{The securities issued by the companies we feature should be seen as high risk; if you choose to invest, despite these warnings, you may lose your entire investment. You must be aware of the risks and be willing to accept them in order to invest in financial instruments, including stocks, options, and futures.}

_{NOT PROFESSIONAL ADVICE:}_{By reading this, you agree to all of the following: You understand this to be an expression of opinions and NOT professional advice. You are solely responsible for the use of any content and hold Freedom Financial Research, and all partners, members, and affiliates harmless in any event or claim. While Freedom Financial Research strives to provide accurate and reliable information sourced from believed-to-be trustworthy sources, we cannot guarantee the accuracy or reliability of the information. The information provided reflects conditions as they are at the moment of writing and not at any future date. Freedom Financial Research is not obligated to update, correct, or revise the information post-publication.}

_{FORWARD-LOOKING STATEMENTS:}_{Certain information presented may contain or be considered forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in these statements. There can be no assurance that any such statements will prove to be accurate, and readers should not place undue reliance on such information. These statements are subject to known and unknown risks including those set forth in Helus Pharma's most recent annual information form and other public filings available at www.sedarplus.ca and www.sec.gov. Neither Freedom Financial Research nor Helus Pharma undertake any obligations to update the information presented or to ensure that such information remains current and accurate, except as required under applicable law.}